Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $28.69 Consensus PT from Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $28.6875.

A number of brokerages have recently commented on ROIV. Guggenheim increased their price objective on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price target on shares of Roivant Sciences in a research report on Monday, February 9th. Leerink Partners boosted their price objective on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Finally, Weiss Ratings lowered shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 9th.

Insiders Place Their Bets

In other news, Director Daniel Allen Gold sold 375,784 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $26.50, for a total value of $9,958,276.00. Following the transaction, the director directly owned 15,127,329 shares of the company’s stock, valued at approximately $400,874,218.50. This represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.49, for a total value of $5,298,000.00. Following the sale, the chief executive officer owned 1,654,597 shares of the company’s stock, valued at approximately $43,830,274.53. This represents a 10.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,318,014 shares of company stock valued at $315,727,023 in the last 90 days. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Pacer Advisors Inc. boosted its position in shares of Roivant Sciences by 24.0% in the fourth quarter. Pacer Advisors Inc. now owns 70,259 shares of the company’s stock valued at $1,525,000 after acquiring an additional 13,609 shares during the period. Dorsey Wright & Associates acquired a new position in Roivant Sciences during the 4th quarter valued at $8,162,000. Invesco Ltd. boosted its holdings in Roivant Sciences by 28.9% in the 4th quarter. Invesco Ltd. now owns 2,281,487 shares of the company’s stock valued at $49,508,000 after purchasing an additional 512,129 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in Roivant Sciences in the 4th quarter worth $227,000. Finally, Empowered Funds LLC bought a new position in shares of Roivant Sciences during the 4th quarter worth about $396,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Trading Down 0.6%

NASDAQ ROIV opened at $28.49 on Tuesday. The company has a 50-day moving average price of $23.80 and a two-hundred day moving average price of $19.32. Roivant Sciences has a 52 week low of $8.73 and a 52 week high of $29.20. The stock has a market cap of $20.39 billion, a price-to-earnings ratio of -24.35 and a beta of 1.22.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.